Kewaunee Scientific Corp (KEQU)
NASDAQConsumer DiscretionaryFurnishings, Fixtures & AppliancesSnapshot 2026-09-04
$36.99+0.52%
Close 2026-09-04 · 1-day change
NASDAQConsumer DiscretionaryFurnishings, Fixtures & AppliancesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Kewaunee Scientific has a low price-to-earnings ratio near 11. Analysts expect revenue growth around 8% next year. The company recently beat earnings twice, showing some strength. Free cash flow yield is strong at 14%, supporting financial health.
Backlog signals a tough year ahead, which may hurt revenue growth. The company cut EPS guidance from $5.37 to $3.43 next year. The sector is facing headwinds, and the stock is down nearly 12% from its high.
The stock trades about 38% below our fair value near $59. The market expects about 8% revenue growth, which aligns with consensus. Our view is cautious given recent guidance cuts and backlog concerns.
Breaks if: EPS guidance falls below $3.43 for fiscal year 2027
Breaks if: Free cash flow yield falls below 10%
Breaks if: Revenue growth falls below 6% YoY next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable growth opportunity with some risks. KEQU is focused on executing its growth strategy while managing its balance sheet, but faces challenges in the current economic environment.
The market currently reflects a valuation that is cheap compared to peers, with a slight expectations gap. This suggests that investors may not be fully pricing in potential risks or growth opportunities.
Management is on track with its growth strategy, evidenced by recent revenue growth. However, there is a notable risk of missing earnings expectations, which has been a trend in recent quarters.
The future performance of KEQU will depend on its ability to integrate the Nu Aire acquisition successfully and the overall health of the Consumer Discretionary sector. Additionally, inflation trends and guidance updates will be critical factors to monitor.
Over the next 1 to 3 years, KEQU's performance will be influenced by its execution on strategic priorities and external economic conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation fell by 11.5 points (from 68.9 to 57.4).
Yes, our read has strengthened. Kewaunee Scientific posted record revenue of $282 million. This supports its growth strategy and future investments. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.